Please login to the form below

Not currently logged in

Xarelto effective in reducing blood clots

A study shows that following total knee replacement surgery, Xarelto reduces the relative risk of blood clots when compared with enoxaparin

A study published in The Lancet shows that following total knee replacement surgery, Xarelto (rixaroxoban) reduces the relative risk of blood clots by more than 30 per cent when compared with enoxaparin.

The results come from the Phase III RECORD4 trial comparing Bayer's anticoagulant Xarelto, administered as a once-daily tablet with enoxaprin, a twice-daily injection.

Professor Beverley Hunt, consultant haematologist and medical director of Lifeblood said: "We want to ensure that every adult admitted to hospital in the UK receives appropriate prevention against hospital-acquired clots, which are the number one cause of preventable deaths in hospital care. We welcome rivaroxaban which has the advantages of being a tablet and has proven to be superior to the gold standard in clinical trials after knee replacements"

As Xarelto is in tablet form it does not need to be administered by a healthcare practitioner, unlike the injectable, twice-daily enoxaparin.

"Blood clots after major orthopaedic surgery remain a serious clinical problem," said Professor Ajay Kakkar, professor of surgical sciences at the Barts and the London School of Medicine and Dentistry, and director of the Thrombosis Research Institute. "Rivaroxaban will add to our armamentarium of thrombosis-preventing strategies and help in their use after hospital discharge," he continued.

Xarelto is approved in the EU, among other countries, for the prevention of venous thromboembolism (VTE) in adults undergoing elective hip or knee replacement surgery.

6th May 2009


Featured jobs

Subscribe to our email news alerts


Add my company

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018